A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

IsraelRecruitingPHASE3

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell · Leukemia, Chronic Lymphocytic · Small-Cell Lymphoma · Lymphoma, Small Lymphocytic · CLL · SLL

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Highlands Oncology Group ( Site 5405), Springdale, Arkansas, United States

    Study coordinator · 479-872-8130
  • MemorialCare Health System - Long Beach Medical Center ( Site 5421), Long Beach, California, United States

    Study coordinator · 562-933-7866
  • Memorial Hospital West ( Site 5410), Pembroke Pines, Florida, United States

    Study coordinator · 954-844-8318
  • Oregon Health and Science University ( Site 5425), Portland, Oregon, United States

    Study coordinator · 503-494-5058
  • Medical Oncology Associates, PS ( Site 5406), Spokane, Washington, United States

    Study coordinator · 509-462-2273
  • University of Wisconsin Hospital and Clinics-Carbone Cancer Center ( Site 5423), Madison, Wisconsin, United States

  • Instituto Alexander Fleming ( Site 1005), Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

    Study coordinator · +541132218900
  • Instituto de Investigaciones Clínicas Mar del Plata ( Site 1007), Mar del Plata, Buenos Aires, Argentina

    Study coordinator · +542234963224
  • Sanatorio Parque ( Site 1003), Rosario, Santa Fe Province, Argentina

    Study coordinator · +543414200222
  • Centro Medico Fleischer ( Site 1006), Buenos Aires, Argentina

    Study coordinator · +541148544097
  • Hospital Aleman-oncohematologic diseases ( Site 1001), Buenos Aires, Argentina

    Study coordinator · +541148277000
  • Royal Adelaide Hospital ( Site 1104), Adelaide, South Australia, Australia

    Study coordinator · +61870740000
  • Western Health-Sunshine & Footscray Hospitals-Cancer Services-Cancer Research ( Site 1103), Melbourne, Victoria, Australia

    Study coordinator · +61383959130
  • UZ Leuven-Hematology ( Site 1200), Leuven, Vlaams-Brabant, Belgium

    Study coordinator · +32 16/338544
  • ZAS Cadix ( Site 1203), Antwerp, Belgium

    Study coordinator · +32 3/339 76 38
  • ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO-Pesquisa Clinica ( Site 1308), São Paulo, Brazil

  • The Moncton Hospital ( Site 1414), Moncton, New Brunswick, Canada

    Study coordinator · 506-870-2404
  • Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre ( Site 1402), Greenfield Park, Quebec, Canada

    Study coordinator · 450-466-5000 x3226
  • Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer ( Site 1410), Sherbrooke, Quebec, Canada

    Study coordinator · 819-346-1110 x12811
  • Biocenter ( Site 1507), Concepción, Biobio, Chile

    Study coordinator · +56412858421
  • IC La Serena Research ( Site 1506), La Serena, Coquimbo Region, Chile

    Study coordinator · +56958646664
  • Centro de Estudios Clínicos SAGA-CECSAGA ( Site 1509), Santiago, Region M. de Santiago, Chile

    Study coordinator · +56991612199
  • FALP-UIDO ( Site 1500), Santiago, Region M. de Santiago, Chile

    Study coordinator · 56224205098
  • Clínica Inmunocel ( Site 1511), Santiago, Region M. de Santiago, Chile

    Study coordinator · +56224376600
  • Fundación Valle del Lili ( Site 1703), Cali, Valle del Cauca Department, Colombia

    Study coordinator · 57 3133288646
  • Hopital Claude Huriez - CHU de Lille ( Site 2107), Lille, Nord, France

    Study coordinator · +333 20 44 59 62
  • Centre Hospitalier Universitaire Estaing ( Site 2105), Clermont-Ferrand, Puy-de-Dome, France

    Study coordinator · +33473750065
  • CHD Vendee ( Site 2100), La Roche-sur-Yon, Vendee, France

    Study coordinator · +33251446572
  • Klinikum Mutterhaus der Borromäerinnen-Innere Medizin I ( Site 2203), Trier, Rhineland-Palatinate, Germany

    Study coordinator · +496519472571
  • Universitätsklinikum Leipzig-Medical Department I - Hematology and Celltherapy ( Site 2201), Leipzig, Saxony, Germany

    Study coordinator · +49 341 97 13131
  • Rambam Health Care Campus ( Site 2801), Haifa, Israel

    Study coordinator · +97247771514
  • Hadassah Medical Center-Hemato-Oncology ( Site 2812), Jerusalem, Israel

    Study coordinator · +972-539101736
  • Sheba Medical Center-Hemato Oncology ( Site 2809), Ramat Gan, Israel

    Study coordinator · +972-35308401
  • Sourasky Medical Center ( Site 2811), Tel Aviv, Israel

    Study coordinator · +97237772649
  • Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo ( Site 2906), Alessandria, Italy

    Study coordinator · +390131206440
  • Ospedale San Raffaele-Programma di Ricerca Strategica sulla LLC ( Site 2902), Milan, Italy

    Study coordinator · +390226436119
  • Arcispedale Santa Maria Nuova-Hematology ( Site 2900), Reggio Emilia, Italy

    Study coordinator · +390522295654
  • Centro de Infusion Superare ( Site 3314), Mexico City, Mexico City, Mexico

    Study coordinator · +52 55 5264 6440
  • Health Pharma Professional Research S.A. de C.V: ( Site 3301), Mexico City, Mexico City, Mexico

    Study coordinator · +52 55 7586 4856
  • Centro de Investigacion Clinica Chapultepec ( Site 3309), Morelia, Michoacán, Mexico

    Study coordinator · +52 443 147 8545
  • Auxilio Mutuo Cancer Center ( Site 3900), San Juan, Puerto Rico

    Study coordinator · 7877582000
  • Alberts Cellular Therapy. ( Site 4401), Pretoria, Gauteng, South Africa

    Study coordinator · +27 12 993 2555
  • Groote Schuur Hospital ( Site 4400), Cape Town, Western Cape, South Africa

    Study coordinator · +27727689024
  • Haemalife ( Site 4407), Kuilsriver, Western Cape, South Africa

    Study coordinator · +27 21 900 6277
  • Instituto Catalan de Oncologia - Hospital Duran i Reynals-Haematology Department ( Site 4601), L'Hospitalet Del Llobregat, Barcelona, Spain

    Study coordinator · +34932607750
  • HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID ( Site 4602), Pozuelo de Alarcón, Madrid, Spain

    Study coordinator · 914521900
  • HOSPITAL CLINICO DE VALENCIA-HEMATOLOGY ( Site 4603), Valencia, Valenciana, Comunitat, Spain

    Study coordinator · 961973930
  • Ege Universitesi Hastanesi ( Site 4902), Bornova, İzmir, Turkey (Türkiye)

    Study coordinator · +905325566128
  • Namik Kemal University Medical Faculty-Hematology ( Site 4912), Tekirdağ, Tekirdas, Turkey (Türkiye)

    Study coordinator · 0090 282 250 50 50
  • Ankara Universitesi Tip Fakultesi Hastanesi-hematology ( Site 4913), Ankara, Turkey (Türkiye)

  • Mega Medipol-Hematology ( Site 4904), Istanbul, Turkey (Türkiye)

    Study coordinator · 0212 444 70 44
  • TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi ( Site 4906), Istanbul, Turkey (Türkiye)

    Study coordinator · 0090 216 606 52 00
  • City Hospital, Nottingham University Hospitals-Hematology ( Site 5002), Nottingham, England, United Kingdom

    Study coordinator · +44115969116972549
  • University College London Hospital-Cancer Clinical Trials Unit ( Site 5001), London-Camden, London, City of, United Kingdom

    Study coordinator · +4420 3447 2528
Study leads
  • Medical Director

    Study Director

    Merck Sharp & Dohme LLC